NCT04883593

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TA103 and Placebo Control in the Treatment of Tinea Pedis.

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.

Detailed description

A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing TA103 and the placebo control in the treatment of tinea pedis.

Conditions

• Tinea Pedis

Interventions

Type	Name	Description
DRUG	TA103	The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.
DRUG	Placebo Control	The assigned Investigational Product will be applied to the skin between, under, all over the toes, sole and sides of the entire foot. Both feet are to be treated in the same way, even if the skin looks healthy and lesions are present on one foot only.

Timeline

• Start date: 2020-09-03
• Primary completion: 2021-02-20
• Completion: 2021-02-20
• First posted: 2021-05-12
• Last updated: 2021-05-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study